// App-Quantinova.ai

7506 : PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).

Researchers

Presenter

  • Thomas E. Witzig

Principal Investigators

  • Luigi Rigacci

  • Tongyu Lin

  • Takashi Ikeda

  • Anna Vanazzi

  • Masayuki Hino

  • Yuankai Shi

  • Jiri Mayer

  • Luciano J Costa

  • Carlos DANIEL Bermudez

  • Jun Zhu

  • David Belada

  • Kamal Bouabdallah

  • Joseph Gergi Kattan

  • Cassandra Wu

  • Jenna Fan

  • Anne-Laure Louveau

  • Maurizio Voi

  • Franco Cavalli

Medical Centers

  • Mayo Clinic, Rochester, MN

  • National Cancer Center Hospital, Tokyo, Japan

  • Hematology, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy

  • Cancer Center Sun Yat Sen University, Guangzhou, China

  • Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka 4111-8777, Japan

  • Division of Clinical Haemato-Oncology, Milano, Italy

  • Department of Clinical Hematology and Diagnostics, Osaka University Graduate School of Medicine, Osaka, Japan

  • Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China

  • University Hospital Brno, Brno, Czech Republic

  • University of Alabama, Birmingham, AL

  • Instituto Nacional de Cancerologia, Bogota, Colombia

  • Department of Lymphoma, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China

  • Fourth Department of Internal Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

  • Department of Haematology, CHU Haut-Leveque, Bordeaux, France

  • Hotel-Dieu de France University Hospital, Beirut, Lebanon

  • Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharma, Paris, France

  • Novartis Oncology, East Hanover, NJ

  • Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Locations

  • Czech Republic

  • China

  • Japan

  • Italy

  • Switzerland

  • Lebanon

  • United States

  • France

  • Colombia

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • Negative

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT00790036

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved